Demecarium

CHEMBL1201229 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
556.8 g/mol
LogP
6.6
Phase
4

A long-acting irreversible cholinesterase inhibitor eye drop used for chronic open-angle glaucoma and accommodative esotropia in children. Its use has largely been replaced by more modern glaucoma therapies due to its side effect profile.

Molekularmasse

556,8000 g/mol

LogP

6,60

TPSA

59,10 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Wirkmechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1

InChI

InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2

Molecular Formula

C32H52N4O4+2

HBD / HBA

- / 4

Rotierbare Bindungen

17

Schwere Atome

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A long-acting irreversible cholinesterase inhibitor eye drop used for chronic open-angle glaucoma and accommodative esotropia in children. Its use has largely been replaced by more modern glaucoma therapies due to its side effect profile.

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Yes, Demecarium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201229. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5966. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.